Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.22
- Piotroski Score 4.00
- Grade Buy
- Symbol (MGX)
- Company Metagenomi, Inc. Common Stock
- Price $1.88
- Changes Percentage (3.02%)
- Change $0.06
- Day Low $1.75
- Day High $1.94
- Year High $12.74
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $14.50
- High Stock Price Target $22.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-68,255,000
Income Statement
Quarterly
Annual
Latest News of MGX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
BlackRock, Global Infrastructure Partners, Microsoft, MGX Launch AI Partnership
BlackRock, Global Infrastructure Partners, MGX, and Microsoft are forming a partnership to invest up to $100 billion in expanding AI data centers and energy infrastructure. The initiative aims to enha...
By MarketWatch | 2 months ago -
Estimating The Intrinsic Value Of Mount Gibson Iron Limited (ASX:MGX)
Mount Gibson Iron's current share price of AU$0.42 may indicate fair value. Using the Discounted Cash Flow model, the intrinsic value is estimated. Factors such as dividend payments, growth rates, and...
By Yahoo! Finance | 5 months ago
